Login / Signup

T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review.

Benjamin DuongPratyush BanskotaGerald S Falchook
Published in: Journal of immunotherapy and precision oncology (2024)
T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) is a receptor found on a multitude of immune cells and is commonly overexpressed in patients with cancer. Due to its selective expression in immune cells and its preliminary efficacy in preclinical models, TIM-3 is a promising target as a treatment for cancer. Both monotherapy and combination regimens are being developed and are currently under investigation. This clinical review seeks to summarize and compile past, present, and future TIM-3 inhibitors in clinical trials.
Keyphrases
  • clinical trial
  • binding protein
  • combination therapy
  • open label
  • protein protein
  • palliative care
  • amino acid
  • randomized controlled trial
  • stem cells
  • squamous cell
  • phase iii
  • small molecule
  • study protocol